Igc commences phase 2 clinical trials evaluating drug candidate igc-ad1 for the treatment of agitation in dementia from alzheimer's disease

Potomac, md.--( business wire )--india globalization capital, inc. (nyse american: igc) (“igc” or the “company”), announced that it has begun “a phase 2, multi-center, double-blind, randomized, placebo-controlled, trial of the safety and efficacy of igc-ad1 on agitation in participants with dementia due to alzheimer's disease”.
IGC Ratings Summary
IGC Quant Ranking